Eli Lilly investors are eager for Foundayo insight after early launch data [Yahoo! Finance Canada]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance Canada
financial figures reported on Thursday: insight into the launch of weight-loss pill Foundayo. U.S. sales of the hotly anticipated obesity offering, a ?rival to Novo Nordisk's Wegovy pill, began in early April, so Foundayo data will not be included in Lilly's first-quarter financials. Several more ?weeks of prescription data is likely needed to determine Foundayo's early sales trajectory, one investor said. But the pill will still be top of mind, especially with initial data prompting some analysts to ?say Foundayo's launch is lagging Novo Nordisk's oral Wegovy, which hit the market in January. "We're two weeks into the launch, so it is really too early in my view to make a concrete call on the strength of the launch," said BMO Capital Markets analyst Evan Seigerman. "You're really going to want to listen to how CEO Dave Ricks frames how the launch is going." The initial data may not capture direct-to-consumer sales, and investors typically need five to six weeks of data for ?a
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Denecimig (Mim8) significantly reduced annualized bleeding rate in people with hemophilia A, regardless of inhibitor status, in phase 3 data published in NEJM [Yahoo! Finance]Yahoo! Finance
- Eli Lilly Slips as Canada Approves Generic Weight-Loss Drug [Yahoo! Finance]Yahoo! Finance
- Eli Lilly investors are eager for Foundayo insight after early launch data [Yahoo! Finance]Yahoo! Finance
- Wegovy's Early Lead To Narrow As Eli Lilly Prepares Foundayo Launch [Seeking Alpha]Seeking Alpha
- Health Canada approves first generic version of Novo Nordisk's Ozempic [BNN Bloomberg (Canada)]BNN Bloomberg
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 4/27/26 - Form 6-K
- 4/20/26 - Form 6-K
- 4/20/26 - Form 6-K
- NVO's page on the SEC website